Table 1 Demographic, laboratory and clinical characteristics of the 381 patients who received BMD measurement.
| Sociodemographic variables | |
|---|---|
| Mean (SD) age, years (n = 381) | 55 (13) |
| Mean (SD) BMI, kg/m2 (n = 378) | 26 (4) |
| Women, % (n = 381) | 71 |
| Postmenopausal, % (n = 269) | 68 |
| Mean (SD) age at menopause, years | 47 (5) |
| Premature menopause, % | 7 |
| Surgical ovariectomy, % | 33 |
| Premature ovarian failure, % | 67 |
| Caucasian, % (n = 381) | 93 |
| Current smoker, % (n = 381) | 36 |
| Median (IQR) number of cigarettes/day | 13 (18–20) |
| Current alcohol user, % (n = 381) | 52 |
| Median (IQR) number of glasses of alcohol/day | 7 (3–14) |
| Previous clinical fractures >30 years, % (n = 381) | 14 |
| Postmenopausal fractures, % (n = 269) | 4 |
| Familial (first‐degree relatives) osteoporosis, % (n = 379) | 15 |
| Disease‐related variables | |
|---|---|
| Median (IQR) symptom duration, weeks (n = 381) | 23 (13–53) |
| Positive IgM rheumatoid factor, % (n = 381) | 64 |
| Mean (SD) DAS44 (n = 381) | 4.4 (0.9) |
| Mean (SD) HAQ score, 0–3 scale (n = 370) | 1.4 (0.7) |
| Median (IQR) total SHS, 0–448 scale (n = 375) | 4.0 (1.5–8.5) |
| Erosive disease, % (n = 375) | 72 |
| Mean (SD) CRP, mg/L (n = 352) | 37 (42) |
| Mean (SD) calcium intake, mg/day (n = 378) | 924 (356) |
| Calcium supplementation, % (n = 381) | 2 |
| Mean (SD) 25‐OH vitamin D level, nmol/L (n = 323) | 51 (30) |
| Vitamin D supplementation, % (n = 381) | 1 |
| HRT, % (n = 271) | 21 |
| Median (IQR) duration used, years | 5 (2–14) |
| Bisphosphonates use, % (n = 381) | 1 |
| Spine L2‐4 (n = 378) | |
| Mean (SD) T score SD) | −0.44 (1.5) |
| Mean (SD) Z score | 0.29 (1.5) |
| Total hip (n = 359) | |
| Mean (SD) T score | −0.43 (1.3) |
| Mean (SD) Z score | 0.26 (1.2) |
BMI, body mass index; CRP, C‐reactive protein; DAS, Disease Activity Score, HAQ, Health Assessment Questionnaire; HRT, hormone replacement therapy; SHS, Sharp–van der Heijde Score.